Biotechnology · Lexington, Massachusetts, United States
$11.23
-3.93% (-$0.46)2026-10-13
Smart-Money SignalNeutral · 55/100— Insiders are net buyers over 90 days ($15K, 2 buys vs 1 sale)
Revenue$0
Net Income-$28.7M
EPS$-2.66
Market Cap$222.7M
Price Performance
Historical data including institutional events
Company Profile
J
Jasbir Seehra
CEO & Executive Director
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-Ã signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept; and Takeda Pharmaceuticals U.S.A., Inc. to develop, manufacture, and commercialize elritercept and certain derivative compounds. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
- Founded
- 2015
- Employees
- 78
- Headquarters
- Lexington, Massachusetts, United States
- Website
- www.kerostx.com
Peer ComparisonRevenue ($B)
▾Loading company sections...